Category: About VRD

About VRD – Vrd.co

Global Virtual Retinal Display(VRD) Market 2020 Key Drivers, Research Objectives, Future Prospects and Growth Potential to 2025

The MarketWatch News Department was not involved in the creation of this content. Dec 09, 2020 (CDN Newswire via Comtex) — This intensive research report entitled Global Virtual Retinal Display(VRD) Market 2020 by Company, Type and Application, Forecast to 2025[1] compiled and published by MarketQuest.biz entails a market synopsis and offers a definition & outline of the market. The report...

READ MORE Global Virtual Retinal Display(VRD) Market 2020 Key Drivers, Research Objectives, Future Prospects and Growth Potential to 2025

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio

RARITAN, N.J., Nov. 5, 2020 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020. In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen...

READ MORE Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio

New DARZALEX® (daratumumab) Data from GRIFFIN Study Show High Response Rate and Depth of Response in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant-Eligible

BOSTON, Sept. 15, 2019 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized Phase 2 GRIFFIN (MMY2004[1]) study showing that the addition of DARZALEX® (daratumumab) to bortezomib, lenalidomide and dexamethasone (VRd) induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation (ASCT) compared...

READ MORE New DARZALEX® (daratumumab) Data from GRIFFIN Study Show High Response Rate and Depth of Response in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant-Eligible

Americas Will Continue to Dominate the Global Virtual Retinal Display Market Through 2020: Technavio

LONDON–(BUSINESS WIRE[1])–The global virtual retinal display (VRD) market[2] is expected to grow at a CAGR of 3.51% during the forecast period, according to Technavio’s latest report. In this report, Technavio[3] covers the market outlook and growth prospects of the global VRD[4] market for 2016-2020. To calculate the market size, the report considers revenue generated from shipment of VRD devices for...

READ MORE Americas Will Continue to Dominate the Global Virtual Retinal Display Market Through 2020: Technavio

Generated by Feedzy